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Our aim was to evaluate the results of automated sur-
veillance of Lyme neuroborreliosis (LNB) in Denmark 
using the national microbiology database (MiBa), and 
to describe the epidemiology of laboratory-confirmed 
LNB at a national level. MiBa-based surveillance 
includes electronic transfer of laboratory results, in 
contrast to the statutory surveillance based on manu-
ally processed notifications. Antibody index (AI) test-
ing is the recommend laboratory test to support the 
diagnosis of LNB in Denmark. In the period from 2010 
to 2012, 217 clinical cases of LNB were notified to the 
statutory surveillance system, while 533 cases were 
reported AI positive by the MiBa system. Thirty-five 
unconfirmed cases (29 AI-negative and 6 not tested) 
were notified, but not captured by MiBa. Using MiBa, 
the number of reported cases was increased almost 2.5 
times. Furthermore, the reporting was timelier (median 
lag time: 6 vs 58 days). Average annual incidence of 
AI-confirmed LNB in Denmark was 3.2/100,000 popu-
lation and incidences stratified by municipality ranged 
from none to above 10/100,000. This is the first study 
reporting nationwide incidence of LNB using objec-
tive laboratory criteria. Laboratory-based surveillance 
with electronic data-transfer was more accurate, com-
plete and timely compared to the surveillance based 
on manually processed notifications. We propose 
using AI test results for LNB surveillance instead of 
clinical reporting. 
Introduction
Borrelia species, known to cause Lyme borreliosis, are 
collectively known as Borrelia burgdorferi sensu lato. 
B. burgdorferi sensu stricto is the cause of Lyme borre-
liosis in North America, whereas B. afzelii and B. garinii 
cause most European cases [1]. Differences in the clini-
cal presentation of Lyme borreliosis in North America 
and Europe are ascribed to differences in the predomi-
nant species. One important systemic manifestation of 
Lyme borreliosis is Lyme neuroborreliosis (LNB), which 
is a clinically characteristic neurological syndrome. 
Notably LNB is much more common in Europe where B. 
garinii is frequently the causative agent. In Denmark B. 
afzelii has been isolated from patients with erythema 
migrans and B. garinii from patients with LNB [2]. The 
disease is transmitted by the hard tick (Ixodes ricinus 
or I. persulcatus). The abundance of I. ricinus is deter-
mined by complex interaction with many factors includ-
ing wildlife, geography and climate [3]. According to 
the clinical European case definition developed by the 
European Federation of Neurological Societies (EFNS), 
and also written stated by the European Study group for 
Lyme Borreliosis (ESGBOR) under the European Society 
for Clinical Microbiology and Infectious Diseases, dem-
onstration of intrathecal antibody production (antibody 
index, AI) is essential for the diagnosis of LNB [4,5]. In 
patients with short duration of clinical disease, anti-
body response may be weak or absent [5]. The original 
development of a new assay and diagnostic criteria to 
diagnose patients with LNB with AI in Denmark was 
described by Klaus Hansen and co-workers [6-9] and 
this assay has been found sensitive and specific 
[5,8-10].
In Denmark, surveillance of LNB started in 1991 when 
the Danish Health and Medicines Agency decided to 
make LNB a mandatory clinical notifiable disease to 
Statens Serum Institut (SSI), as LNB was considered 
to be the most common severe clinical manifesta-
tions of Lyme borreliosis. LNB is relevant for surveil-
lance, as it is of public health interest to follow trends 
due to climate change or altered outdoor behaviour in 
order to adopt appropriate preventive measures. The 
incidences of the other disseminated manifestations 
of Lyme borreliosis such as acrodermatitis, carditis, 
Lyme arthritis and lymphocytoma are not known in 
Denmark. The incidence of patients suspected of these 
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other manifestations was however 47/100.000, but a 
low seropositivity rate, similar to healthy controls, was 
found in consecutive patients seen in general practice, 
which suggests a low incidence and poor positive pre-
dictive value of serology in most cases [11].
The current statutory Danish notification system for 
infectious diseases (DNSID) is based on collection of 
paper forms completed by the physician treating the 
patient; the forms are sent by mail to the Department 
of Infectious Disease Epidemiology at SSI and the 
Regional Medical Officer of Health. SSI sends remind-
ers to the clinicians if intrathecal antibody produc-
tion has been detected by the SSI laboratory and no 
notification has been received within a certain time-
frame. From 2011 to 2012, 44% of the notifications was 
received only after a reminder had been sent. Due to 
increased testing at the regional microbiological labo-
ratories, SSI is responsible for a decreasing fraction 
of the AI tests in Denmark, and therefore the current 
surveillance system for LNB is neither timely nor com-
plete, even considering the sending of reminders.
The Danish microbiology database (MiBa) has recently 
been developed and has since 2010 received electronic 
copies of all reports from all Danish departments of 
clinical microbiology [12]. MiBa has several objectives 
including improving the national laboratory-based 
surveillance [10]. The aim of the present study was to 
assess MiBa for laboratory-based surveillance of LNB, 
including a comparison with the prevailing system 
based on manually-processed clinical notifications. 
Furthermore, we use the data from MiBa to describe the 
epidemiology of laboratory-confirmed LNB in Denmark.
Methods
The study period was from January 2010 to December 
2012 and the study population was the population of 
Denmark.
Figure 1
Flowchart of patients suspected for Lyme neuroborreliosis (LNB) included in the study, Denmark, 2010–2012 (n=13,929 
suspected patients)
AI: antibody index; DNSID: Danish notification system for infectious diseases; MiBa: Danish microbiology database
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Data sources
The statutory Danish notification system for infectious 
diseases
DNSID is a case-based database including informa-
tion on the civil registration number (CPR number) of 
the case, date of disease-onset, symptoms, labora-
tory results as well as sequelae. The CPR number is a 
unique identification number given to each person liv-
ing in Denmark.
Both confirmed and probable cases (see below) were 
included in the DNSID dataset extracted for the pre-
sent study, as both, so far, have been included in the 
national surveillance.
The Danish microbiology database
MiBa receives real-time electronic copies of all reports 
from all Danish departments of clinical microbiology 
[12]. The data model and basic principles have been 
described previously [12,13]. Within MiBa local codes 
are automatically mapped to national shared codes 
before data extraction. All reports include the CPR 
number of the patient.
In Denmark a total 11 laboratories performed AI tests. 
At the time of the study, nine of these reported to MiBa 
through their microbiology laboratory information sys-
tems. The two remaining laboratories included one bio-
chemistry laboratory that did not report to MiBa, and 
one laboratory that had technical problems with the 
transfer protocol during the first two years. To obtain 
complete nationwide data, data on AI test results were 
acquired directly from the two latter laboratories and 
merged with the MiBa data. This merged dataset is 
referred to as the MiBa dataset hereafter.
The Danish civil registration system
Using the CPR number information on age, 
sex, address, and municipality was obtained. 
Information on population size was obtained from 
Statistics Denmark (www.dst.dk). To represent the mid-
dle of the study period, data was retrieved for the first 
quarter of 2011, were Denmark had a total population 
of 5.56 million people.
Definitions and data management
The statutory case definition for LNB in DNSID is as 
follows: 
•	  Confirmed case: patient with clinical symptoms 
con sistent with LNB and a positive AI test. 
•	  Probable case: patient with clinical symptoms con-
sistent with LNB and borrelia antibodies in serum. 
•	  Concerning the probable cases the AI is either 
negative or not done, but the detection of serum-
antibodies is required. 
•	  Case definition for LNB in MiBa: 
•	  A patient with one or more AI tests positive for 
Borrelia IgG or IgM antibodies or both. 
Figure 2
Annual numbers of Lyme neuroborreliosis cases identified in the Danish microbiology database (MiBa) from 2010 to 2012 
and annual numbers of notified cases, Denmark, 2000–2012
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Figure 3
Monthly numbers of antibody index (AI) positive Lyme neuroborreliosis (LNB) cases and average annual incidence of cases 
and patients tested, Denmark, 2010–2012
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Data management
Patients residing in Greenland and patients with tem-
porary CPR numbers, including foreign travellers, were 
excluded from all datasets.
The raw MiBa dataset included results from more than 
one test report per patient. This raw dataset was trans-
formed into a dataset with only one record per CPR 
number (case) according to the following rules:
Each patient was classified as IgG positive, IgM posi-
tive or both IgG-and-IgM positive, based on the accu-
mulated AI-results of one or more reports. If a test 
result was stated as inconclusive it was considered 
as negative. A patient was only included once during 
the three year study period with the first positive test 
as a case-defining event. A patient with only negative 
AI tests was included as a LNB negative patient with 
the date of the first test performed. The total number 
of tests performed per patient was registered. The age 
was calculated as age at the date of disease.
Reports on tests that for some reason were not per-
formed (e.g. sample tube broken during transport) 
were excluded from the dataset.
Intrathecal antibody production
For this study, with the purpose of surveillance, the 
conclusion by the laboratory in the report was consid-
ered valid regardless of the type of assay and method 
of index calculation. All laboratories except one used 
an assay based on native purified flagella antigen 
(IDEIA LNB IgG/IgM assay, Oxoid, Cambridgeshire, 
United Kingdom). The index calculation is specified 
by the manufacturer with the formula: Index = (ODcsf/
ODserum)*(ODcsf − -ODserum), where ODcsf and 
ODserum is the optical absorbance in the cerebrospi-
nal fluid and the serum, respectively. An index above 
0.3 was considered as positive. If the absolute absorb-
ance (abs.) in the spinal fluid was below 0.150 the 
result was negative in any case. The assay is a capture 
Figure 4
Three year average of annual incidence of Lyme neuroborreliosis antibody index-positive cases, according to municipalities, 
Denmark, 2010–2012
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enzyme-linked immunosorbent assay (ELISA) thus 
the relative abundance of Borrelia specific antibodies 
compared with the total IgG is important for a positive 
result and measurements of total IgG are not needed in 
the algorithm.
Data linkage
Data from DNSID, MiBa, and the Danish civil registra-
tion system was linked using the CPR number.
Timeliness
The timeliness of the two systems was calculated as 
a technical time lag in days from sampling date to the 
date, where information on the case was received at 
SSI, either in the form of a notification or when the test 
result in MiBa was available for data extraction. From 
the DNSID surveillance only confirmed cases were 
included (182 observations). For the MiBa surveillance 
AI positive LNB cases were included.
Statistical methods
Data management was performed using SAS (SAS 
Institute Inc., Cary, North Carolina, United States) and 
statistical analyses were performed in R [14] using 
chi-squared tests and confidence intervals for propor-
tions. Total number of tested patients and LNB cases 
were stratified by age group, sex, and municipality of 
residence and presented per 100,000 population. Also 
annual (cumulative) incidences were calculated per 
100,000 population. For the geographical presentation 
of data QGIS (version 2.4.0) was used.
Ethical considerations
This study was approved by the Danish data protection 
authority as part of a general permission for perform-
ing surveillance studies (registration number 2008–
54–0472) and falls within the regulatory community 
framework for the national surveillance in Denmark 
Figure 5
Three year average of antibody index-tested patients for Lyme neuroborreliosis per 100,000 population according to 
municipalities, Denmark, 2010–2012 
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(the National Board of Health Statutory Order on 
Physicians’ Notification of Infectious Diseases).
Results
Comparison between MiBa and the mandatory 
notification system
According to MiBa from 2010 to 2012 a total of 13,923 
patients were tested by AI and LNB was confirmed in 
533 (4%) patients (Table 1). Of these 172 (32%) were 
only IgG positive, 103 (19%) only IgM positive and 258 
(48%) cases were found positive in both IgM and IgG. 
By contrast, in DNSID only 217 patients were notified 
as LNB in this period (Figure 1, Table 1). Among the 217 
DNSID patients, AI tests were positive for 182, while 
35 patients were either AI negative (29 patients) or not 
tested by AI (6 patients).
When data from DNSID and MiBa were linked, we found 
that of 13,923 tested patients in MiBa, 211 were also in 
DNSID and 182 (83%) of these were AI positive (Table 
1, Figure 1).
Thus in MiBa 351 cases of LNB were identified, which 
had not been registered by the national surveillance. 
These cases were compared with the notified cases 
in Table 2. Among the 351 MiBa cases not notified 65 
(19%) were children (0–15 years of age) and this was 
significantly lower compared with 64 children (29%) 
of 217 cases notified in DNSID (relative risk (RR): 0.63; 
95% confidence interval (CI): 0.47–0.84). Also twelve 
(34%) children were found among the 35 cases noti-
fied where AI was either negative or not performed, 
which may be compared with 65/351 (19%) which were 
AI positive but not notified in DNSID (RR: 1.8; 95% CI: 
1.1–2.9). 
The regional distribution of LNB cases was different 
between notified and unnotified cases identified in 
MiBa.
Since 2000 the average number of notified cases was 
73 per year (Figure 2), corresponding to an annual inci-
dence of LNB of 1.3 cases/100,000 population. The 
average annual number of notified cases from 2010 
to 2012 was 67 and thus comparable to the previous 
years. In the same period, the average number of cases 
identified in MiBa was 178 per year, which yielded an 
annual incidence, of 3.2/100,000.
The median time lag from sampling date to reception 
of the notification by SSI was 58 days (range: 6–613), 
whereas the median time lag from sampling date to 
availability for data extraction in MiBa was five days 
(range: 1–106). The reports with more than 20 days 
delay were due to transfer of samples from some local 
laboratories, for testing at the reference laboratory at 
SSI.
Descriptive epidemiology of Lyme 
neuroborreliosis in Denmark
The data from MiBa show a clear seasonal variation 
of AI-confirmed LNB cases, with lower numbers in the 
period between February to May and peaks in August 
and September (Figure 3A). Also the average number of 
patients tested for AI exhibited seasonal variation with 
lowest number in April (n=278) and highest in August 
(n=468). The average monthly percentage of positive 
test results among patients tested ranged from 1.2% 
in April to 7.4% in September. Thus during winter and 
early spring the diagnostic yield is low.
The age-specific annual incidences of LNB were highest 
among children (5–10 years) and the older age groups 
(55 to 79 years-old) with a peak at 65 to 69 years of 
age (Figure 3B). In contrast, the average annual cumu-
lative age-specific incidence of patients being tested, 
increased with age until 30 years of age, over which 
the incidence of testing was stable and caabout 
100/100,000 population (Figure 3C). 
Geographical distribution
For the geographical distribution of LNB, the DNSID 
data were not used as it they wereas considered unre-
liable due to differences found in reporting frequency 
between regions (Table 2). Based on MiBa data, the 
average annual incidence of LNB stratified by munici-
pality ranged from none to more than 10/100,000 
(Figure 4). ‘Hot spots’ were found in northern Zealand, 
Funen and parts of southern Jutland, and interestingly 
in many of the ‘smaller’ islands (Bornholm, Læsø, 
Samsø, Langeland, Ærø and Fanø). These results were 
not adjusted for differences in age and sex distribution 
between municipalities.
Table 1 
Number of patients tested for Lyme neuroborreliosis 
(LNB) in the Danish microbiology database and number 
of notified cases of LNB in Denmark, 2010–2012
Year
MiBaa DNSID
Testedb Casesc (% positive) Notified casesd
2010 4,347 195 (4.5) 57
2011 4,957 209 (4.2) 101
2012 4,619 129 (2.8) 59
Total 13,923 533 (3.8) 217e
DNSID: Danish notification system for infectious diseases; MiBa: 
Danish microbiology database. 
a  Numbers are based on the MiBa-case dataset. 
b  Number of patients tested by LNB specific antibody index tests. 
c  Number of cases which are antibody index positive for borrelia 
IgM, IgG or both. 
d  Number of cases clinically reported on notifications.
e     Of the total 217 notified patients in DNSID six were probable 
cases, which were not subjected to antibody index testing and 29 
had a negative antibody index test. The remaining 182 notified 
patients had a positive antibody index test. 
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The geographical distribution of LNB (Figure 4) did not 
just reflect differences in frequency of testing (Figure 
5). For example, absence of cases in three municipali-
ties was not explained by lack of testing. Also munici-
palities with the highest incidence of AI testing (Figure 
5) did not have the highest incidence of LNB cases.
Discussion
We compared the existing surveillance system, DNSID, 
based on manually processed notifications with a new 
laboratory-based system, MiBa, automatically compil-
ing all AI test performed on a national level. In spite 
of fundamental differences between the systems, the 
data are comparable since the case definitions for both 
the MiBa-based-system and for confirmed cases in the 
DNSID-based surveillance rely on the AI test for LNB. 
However, the Danish clinical guideline on Lyme borre-
liosis recommends, not only a positive AI, but also a 
lumbar puncture with leucocytosis, for the diagnosis 
of LNB (www.dskm.dk). In MiBa there is no access to 
spinal-fluid leucocyte counts. Leucocytosis in the spi-
nal fluid is an important marker of active disease and, 
if absent, a positive AI probably indicates past infec-
tion. In an earlier study of 3,756 AI tests, the sensitivity 
was estimated to be 88% and specificity 99.7% for LNB 
[8,9,15]. Of 125 AI positive patients, seven patients did 
not show leucocytosis, indicating previous LNB. Thus, 
a case definition solely based on AI testing, would 
provide an adequate specificity for surveillance in a 
Danish context, where previous LNB is rare. The risk 
of reporting past infections as active LNB would be ca 
6%. We therefore consider this concern as less impor-
tant compared with the advantages of an automated 
system.
The existing surveillance includes notifications of both 
probable cases as well confirmed cases (AI-positive). 
On average 12 patients (35 cases/3 years) were notified 
as probable cases per year; these were not captured by 
MiBa. The probable cases were more frequent in chil-
dren less than 16 years-old (Table 2), thus if these 12 
were all true cases, some children would be missed by 
a surveillance based on laboratory reporting of AI posi-
tive results only. In addition, there could be a number of 
patients treated for LNB on a putative diagnosis, which 
were neither tested nor reported. However, this is not 
limitation for surveillance as this group of patients may 
contain misclassified non-LNB patients as well. A sur-
veillance of LNB based on AI results would have a low 
risk of including misclassified cases. We assume that a 
lumbar puncture is only performed, when neurological 
Table 2 
Comparison of the 351 Lyme neuroborreliosis cases identified in the Danish microbiology database (MiBa) but not notified, 
with the 217 notified cases, and annual incidences of all antibody index positive cases in MiBa, Denmark, 2010–2012
Characteristics of 
cases
Notified cases of neuroborreliosis
MiBa cases not 
notified
MiBa cases not notified 
vs notified cases
RR (95% CI)
All cases in MiBa: average 
annual incidence per 
100,000 populationPositive AI
No result or negative 
AI result
Age group in years
0–15 52 12 65 0.63(0.47–0.84) 3.7
16–64 90 17 188 1.08(0.92–1.29) 2.6
≥65 40 6 98 1.32(0.97–1.80) 5.0
Sex
Male 106 18 200 1.08(0.94–1.24) 3.7
Female 76 17 151 1.00(0.82–1.22) 2.7
Region of residence
Capital 76 18 39 0.26(0.18–0.36) 2.3
Zealand 19 2 46 1.35(0.84–2.20) 2.6
Southern Denmark 44 7 138 1.67(1.28–2.21) 5.1
Middle Jutland 23 1 106 2.73(1.83–4.12) 3.4
Northern Jutland 20 6 15 0.36(0.20–0.65) 2.0
Unknowna 0 1 7 NA NA
Total 182 35 351 1.00 3.2
AI: antibody index; CI: confidence interval; NA: not applicable; RR: relative risk.
a  Unknown address of residence.
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symptoms and objective findings justify this invasive 
procedure. Thus testing, without relevant indication, 
which could lead to a low positive predictive value, is 
considered rare.
MiBa receives in principle all test reports from all 
departments of clinical microbiology. However, a few 
tests for infectious diseases are for historical reasons 
still reported by a biochemistry laboratory. This bio-
chemistry laboratory and one department of clinical 
microbiology were unable to report electronically to 
MiBa in the study period. Prospectively, MiBa will be 
complete on LNB AI reports at the national level. The 
automated transfer of all reports frees physicians and 
laboratories from active reporting; and makes sur-
veillance independent of local healthcare personnel 
remembering to do the notification. The present study 
demonstrated underreporting as only 34% of the 533 
AI positive LNB were notified. This probably reflects 
both the workload associated with filling in and send-
ing paper forms and uncertainty on whether LNB is 
notifiable or not. The 533 cases over three years, might 
be slightly underestimated, as we did not take into 
account that it is possible to have more than one epi-
sode of LNB during this period.
The present study described an improved system for 
surveillance of LNB based on objective criteria. It also 
provided an important insight into the epidemiology of 
LNB in Denmark. The incidence of LNB in Denmark was 
found to be more than twice as high as previously esti-
mated. An average annual incidence of 3.2/100,000 in 
Denmark is comparable to a one year Swedish study 
from May 1992 to April 1993 in which the incidence 
of LNB with lymphocytic pleocytosis was found to 
be 2/100,000 [16]. The incidence of AI positivity was 
not reported in this study. In the Würzburg region of 
Germany a yearly incidence for LNB of 3/100,000 may 
be calculated from the study from May 1996 to April 
1997, however the AI was not specified as part of the 
case definitions [17]. In Norway, surveillance of LNB is 
based on a broader case definition comprising clinical 
symptoms with IgM antibodies in serum or spinal fluid 
or evidence of intrathecal production. The Norwegian 
Public Health Institute reports an average incidence of 
6/100,000 per year (www.msis.no). However, includ-
ing cases based on IgM antibodies in serum alone 
may confer problems with specificity and risk of over-
reporting. LNB is rare in the US with an incidence of 
0.07/100,000 per year (www.cdc.org). This is due to 
the occurrence of B. burgdorferi sensu stricto in the 
US and the absence of B. garinii, which is the princi-
pal cause of LNB in Europe [18]. In 2013 the reported 
annual incidence of other causes of bacterial meningi-
tis reported in Denmark was 3.0/100,000 and of these, 
pneumoccal meningitis represented 1.4/100,000 [19]. 
Thus LNB with an incidence of 3.2/100,000 per year 
was the most frequent bacterial cause of infection 
affecting the brain.
LNB is a relatively acute infection and this was 
reflected in the seasonal variation found in the present 
study. The number of LNB cases peaked in August and 
September, in line with a previous Danish study on LNB 
[8].
An advantage of the MiBa-based surveillance is that it 
also includes data on negative test results. This makes 
it possible to study healthcare practices including test-
ing activity on an individual level in a defined popula-
tion and calculate positive rates. We found that testing 
for LNB is common and that 96% were negative. During 
the late winter and the early spring, the diagnostic 
yield is very low. The low positivity rates suggest that 
symptoms suggestive of LNB are caused by other dis-
eases, reflecting the non-specific nature of symptoms 
compatible with LNB.
Interestingly, the population-based LNB incidences 
stratified by age, sex and geography showed a differ-
ent pattern compared with the incidences of patients 
being tested. Testing activity was highest in the age 
group 30 to 79 years, whereas the annual incidence 
of LNB peaked in childhood and again in the older 
age groups (55 to 79 years). Children are presumably 
exposed when they are playing, and a Dutch study 
found that people over 60 years were often bitten by 
ticks in their gardens [20].
The geographical distribution of AI-confirmed LNB has 
not been described previously in Denmark. In the pre-
sent study, the results from MiBa indicated that annual 
incidence varied substantially across the country from 
zero to more than 10/100,000. The finding of hot spots 
on smaller islands has also been described for the 
Finish archipelago forming the region of Åland in the 
Baltic Sea [21]. Three Danish municipalities had no LNB 
cases; this absence could not be explained by lack of 
tested persons as the incidence of tested persons was 
20–100/100,000 (Figure 4 and 5). Compared with the 
statutory notifications, the MiBa-based surveillance 
showed a different geographical distribution of LNB. 
The statutory system is biased by regional differences 
in notification rates; this bias is in part explained by 
SSI only sending reminders for missing notifications, 
based on laboratory results performed at SSI, which 
mainly received samples from the Capital region. This 
was not the case if testing was done at a regional labo-
ratories because the epidemiological department at 
SSI then would be unaware of a possible positive AI. 
One limitation in the description of the geographical 
distribution is that we only have information on place 
of residence, which is not necessarily the place of 
exposure to tick bites.
Whereas the statutory notification system asks for 
information on clinical manifestation and sequelae, 
this information is not available in MiBa. In any case, 
the reporting of this additional clinical information was 
too incomplete to be useful (data not shown). Also ask-
ing for sequelae does not make sense in a reporting 
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system concerning acute disease as this requires a 
longer follow up. However, as the LNB cases in MiBa 
have a unique identifier that allows for linkage with 
other health registries, it will be possible to further 
explore risk factors for developing LNB, clinical mani-
festations and long-term sequelae in ad hoc projects. 
It will also be possible to compare testing for LNB with 
testing for other tick-borne diseases. 
In time of writing, MiBa has accumulated data for four 
years, and procedures for data cleaning, analysis and 
aggregation are being automatised. Soon we will be 
able to calculate baselines and analyse for trends.
It may be relevant also to have surveillance in place 
for other clinical manifestations of Lyme borreliosis 
such as erythema migrans in order to estimate the bur-
den of Lyme borreliosis. This may be possible in the 
future through data-capture from general practition-
ers’ databases and the national patient register, as 
active reporting from clinicians would be difficult to 
motivate and organise. Other systemic manifestations 
in Denmark are rare and have been shown not to con-
tribute significantly to the burden of Lyme borreliosis 
in clinical practice [11]. It was shown that consecutive 
patients with suspected Lyme arthritis had the same 
level of IgG seropositivity as had been found in Danish 
blood donors, indicating that the positive predictive 
value of the serology was negligible [11]. Thus being 
a rare unspecific clinical syndrome lacking a specific 
diagnostic test, Lyme arthritis is not a candidate for 
national surveillance.
Conclusion
In the present study, we found that a surveillance of LNB 
based on data from MiBa was more timely and more 
complete compared with the statutory surveillance 
based on manually processed notifications. We pro-
pose electronic reporting using the AI to replace clini-
cal reporting as the basis of future LNB surveillance. 
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